TIPS reduces hepatic asialoglycoprotein receptor concentration in healthy pigs

Journal of Vascular and Interventional Radiology

Volumn 11, Issue 1, 2000, Pages 123-128

  Stein, Moni ^a   Vera, David R ^b   Stadalnik, Robert C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

Liver, function; Shunts, portosystemic

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; GALACTOSYLNEOGLYCOALBUMIN TC 99M; PENTETATE TECHNETIUM TC 99M;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER PARENCHYMA; LIVER SCINTISCANNING; NONHUMAN; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RECEPTOR DENSITY; SWINE;

EID: 0033965071     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(07)61293-7     Document Type: Article

References (26)

1. Morell AG, Irvine RA, Sternlieb I, Scheunberg IH, Ashwell G. Physical and chemical studies on ceruloplasmin. V. Metabolic studies un sialic acid free ceruloplasmin in vivo. J Biol Chem 1968; 243:155-159.
2. Pricer WE, Ashwell G. The binding of desialylated glycoproteins by plasma membranes of liver. J Biol Chem 1971; 246:4825-4833.
3. Stadalnik RC, Kudo M, Eckelman WC, Vera DR. In vivo functional imaging using receptor-binding radiopharmaceuticals: Technetium-99m-galactosyl-neoglycoalbumin as a model. Invest Radiol 1993; 28:64-70.
4. Stockert RJ, Morell AG. Hepatic binding protein. The galactose specific receptor of mammalian hepatocytes. Hepatology 1983; 3:750-757.
5. Stadalnik RC, Vera DR, Woodle ES, et al. Technetium-99m NGA functional hepatic imaging preliminary clinical experience. J Nucl Med 1985; 26:1233-1242.
6. Pimstone NR, Stadalnik RC, Vera DR, Hutak DP, Trudeau WL. Evaluation of hepatocellular function via receptor mediated uptake of a Technetium-99m labeled asialoglycoprotein analogue. Hepatology 1994; 20: 917-923.
7. Virgolini I, Muller C, Klepetko W, et al. Decreased hepatic function in patients with hepatoma or liver metastases monitored by hepatocyte-specific galactosylated radioligand. Br J Cancer 1990; 61:937-941.
8. Kudo M, Todo A, Ibekubo K Yamamoto K, Vera DR, Stadalnik RC. Quantitative assessment of hepatocellular function via in vivo radioreceptor imaging: Technetium-99m-galactosyl human serum albumin (TcGSA). Hepatology 1993; 17: 814-819.
9. Vera DR, Stadalnik RC, Metz CE, Primstone NP. Diagnostic performance of a receptor-binding radiopharmacokinetic model. J Nucl Med 1996; 37:160-164.
10. Steer CJ. Receptor-mediated endocytosis: mechanisms, biologic function, and molecular properties. In: Zakim D, Boyer TD, eds. Hepatology: a textbook of liver disease. Philadelphia: WB Saunders, 1996; 149-214.
11. Kerlan RK, LaBerge JM, Gordon RL, Ring ER. Transjugular intrahepatic portosystemic shunts: current status. AJR 1995; 164:1059-1066.
12. Coldwell DM, Ring EJ, Rees CR, et al. Multicenter investigation of the role of transjugular intrahepatic portosystemic shunt in management of portal hypertension. Radiology 1995; 196:335-340.
13. Saxon RS, Ross PL, Mendel-Hartvig J, et al. Transjugular intrahepatic portosystemic shunt patency and the importance of stenosis location in the development of recurrent symptoms. Radiology 1998; 207:683-693.
14. Kudo M, Todo A, Ikekubo K, et al. Functional hepatic imaging with receptor-binding radiopharmaceutical: clinical potential as a measure of functioning hepatocyte mass. Gastroenterol Jap 1991; 26:734-742.
15. 99mTc]galactosyl-neoglycoalbumin. J Nucl Med 1991; 31:1169-1176.
16. Vera DR, Scheibe PO, Krohn KA, Trudeau WL, Stadalnik RC. Goodness-of-fit and local identifiability of a receptor-binding radiopharmacokinetic system. IEEE Trans Biomed Engr 1992; BME-39:356-367.
17. Vera DR, Scheibe PO, Banin Y, Stadalnik RC. Local identifiability of a receptor-binding radiopharmacokinetic system having measured parameters of known uncertainty. IEEE Trans Biomed Engr 1994; 41: 891-897.
18. Boyer TD. Is transjugular intrahepatic portasystemic shunt a panacea for the complications of portal hypertension? [editorial; comment]. Hepatology 1998; 28:590-592.
19. Delhaye M, Louis H, Degraef C, et al. Relationship between hepatocyte proliferative ability and liver functional reserve in human cirrhosis. Hepatology 1996; 23:1003-1011.
20. Lotterer E, Moosmuller A, Wengert A, Hahn EG, Fleig WE. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on liver function in patients with alcoholic cirrhosis. [Abstract]. Hepatology 1994; 20:108A.
21. Kira T, Tomiguchi S, Kira M, Ohyama Y, Takahashi M. Quantitative evaluation of the hepatic functional reserve using technetium-99m DTPA-galactosyl human serum albumin before and after transjugular intrahepatic portosystemic shunt. Eur J Nucl Med 1997; 24:1268-1272.
22. Robson SC, Jaskiewicz K, Engelbrecht G, Kahn D, Hickman R, Kirsch RE. Haemostatic and immunological sequelae of portacaval shunt in rats. Liver 1995; 15:293-299.
23. Orloff MJ, Orloff MS, Rambotti M. Treatment of bleeding esophagogastric varices due to extrahepatic portal hypertension: results of portal-systemic shunts during 35 years. J Pediatr Surg 1994; 29:142-151.
24. Kerlan RK Jr, LaBerge JM, Baker EL, et al. Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts. JVIR 1995; 6:917-921.
25. Goldstein JL, Brown MS, Anderson RGW, Russell FG, Schneider WJ. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Ann Rev Cell Biol 1985; 1:1-39.
26. Tuma DJ, Casey CA, Sorrell MF. Effects of ethanol on hepatic protein trafficking: impairment of receptor-mediated endocytosis. Alcohol Alcohol 1990; 25:117-125.